| Literature DB >> 27363014 |
Lin-Yong Zhao1,2, Chang-Chun Li1,2, Lu-Yu Jia3, Xiao-Long Chen1,2, Wei-Han Zhang1,2, Xin-Zu Chen1,2, Kun Yang1,2, Kai Liu1,2, Yi-Gao Wang1,2, Lian Xue1,2, Bo Zhang1, Zhi-Xin Chen1, Jia-Ping Chen1, Zong-Guang Zhou1, Jian-Kun Hu1,2.
Abstract
This study aimed to evaluate the prognostic significance of node ratio (Nr), the ratio of metastatic to retrieved lymph nodes, and to investigate whether a modified staging system based on Nr can improve prognostic ability for gastric cancer patients following gastrectomy. A total of 2572 patients were randomly divided into training set and validation set, and the cutoff points for Nr were produced using X-tile. The relationships between Nr and other clinicopathologic factors were analyzed, while survival prognostic discriminatory ability and accuracy were compared among different staging systems by AIC and C-index in R program. Patients were categorized into four groups as follows: Nr0, Nr1: 0.00-0.15, Nr2: 0.15-0.40 and Nr3: > 0.40. Nr was significantly associated with clinicopathologic factors including macroscopic type, tumor differentiation, lymphovascular invasion, perineural invasion, tumor size, T stage, N stage and TNM stage. Besides, for all patients, Nr and TNrM staging system showed a smaller AIC and a larger C-index than that of N and TNM staging system, respectively. Moreover, in subgroup analysis for patients with retrieved lymph nodes < 15, Nr was demonstrated to have a smaller AIC and a larger C-index than N staging system. Furthermore, in validation analysis, Nr, categorized by our cutoff points, showed a larger C-index and a smaller AIC value than those produced in previous studies. Nr could be considered as a reliable prognostic factor, even in patients with insufficient (< 15) retrieved lymph nodes, and TNrM staging system may improve the prognostic discriminatory ability and accuracy for gastric cancer patients undergoing radical gastrectomy.Entities:
Keywords: gastric cancer; lymph node ratio; prediction; staging
Mesh:
Year: 2016 PMID: 27363014 PMCID: PMC5239459 DOI: 10.18632/oncotarget.9714
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Division of patients by the cutoff points produced by X-tile plot
(A) X-tile plots for lymph node ratio (Nr). The plots illustrate that the produced log-rank χ2 value stratify the node-positive patients into 3 groups by two cutoff points, 0.15 and 0.40. (B), survival curves generated by X-tile plots, show a strong discriminatory capacity, with a χ2 value of 156.7 and a relative risk ratio of 1.00/1.53/2.32.
Patients and clinicopathologic factors
| Training set | Validation set | P* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Factors | Nr0 ( | Nr1 ( | Nr2 ( | Nr3 ( | Total ( | Nr0 ( | Nr1 ( | Nr2 ( | Nr3 ( | Total ( | |||
| Gender | 0.172 | 0.248 | 0.051 | ||||||||||
| Male | 501 | 308 | 361 | 333 | 1503 | 103 | 75 | 71 | 67 | 316 | |||
| Female | 200 | 133 | 123 | 144 | 600 | 54 | 40 | 38 | 24 | 156 | |||
| Age (years) | 0.067 | 0.131 | 0.059 | ||||||||||
| ≥ 60 | 308 | 213 | 209 | 194 | 924 | 73 | 57 | 48 | 52 | 230 | |||
| < 60 | 393 | 228 | 272 | 286 | 1179 | 84 | 58 | 61 | 39 | 242 | |||
| Tumor location | 0.152 | 0.245 | 0.112 | ||||||||||
| Upper third | 175 | 104 | 128 | 117 | 524 | 39 | 20 | 25 | 19 | 103 | |||
| Middle third | 155 | 96 | 96 | 119 | 466 | 38 | 39 | 29 | 22 | 128 | |||
| Lower third | 357 | 232 | 253 | 230 | 1072 | 77 | 55 | 53 | 46 | 231 | |||
| ≥ 2/3 stomach | 14 | 9 | 7 | 11 | 41 | 3 | 1 | 2 | 4 | 10 | |||
| Macroscopic type | < 0.001 | < 0.001 | 0.069 | ||||||||||
| Borrmann 0–II | 395 | 284 | 280 | 225 | 1184 | 85 | 83 | 59 | 17 | 244 | |||
| Borrmann III– IV | 306 | 157 | 204 | 252 | 919 | 72 | 32 | 50 | 74 | 228 | |||
| Tumor differentiation | < 0.001 | < 0.001 | 0.141 | ||||||||||
| Well/Moderately | 138 | 124 | 96 | 56 | 414 | 30 | 25 | 16 | 8 | 79 | |||
| Poorly | 563 | 317 | 388 | 421 | 1689 | 127 | 90 | 93 | 83 | 393 | |||
| Lymphovascular invasion | 0.008 | 0.003 | 0.083 | ||||||||||
| Negative | 437 | 292 | 305 | 275 | 1311 | 90 | 82 | 60 | 42 | 274 | |||
| Positive | 264 | 147 | 179 | 202 | 792 | 67 | 33 | 49 | 49 | 198 | |||
| Perineural invasion | 0.004 | < 0.001 | 0.054 | ||||||||||
| Negative | 560 | 374 | 377 | 368 | 1679 | 121 | 91 | 69 | 67 | 358 | |||
| Positive | 141 | 67 | 107 | 109 | 424 | 36 | 14 | 40 | 24 | 114 | |||
| Adjuvant chemotherapy | 0.087 | 0.271 | 0.090 | ||||||||||
| Present | 254 | 181 | 195 | 207 | 837 | 47 | 45 | 44 | 32 | 168 | |||
| Absent/Unclear | 447 | 260 | 299 | 270 | 1266 | 110 | 70 | 65 | 59 | 304 | |||
| Tumor size | < 0.001 | < 0.001 | 0.102 | ||||||||||
| ≤ 4.5 cm | 234 | 191 | 178 | 99 | 702 | 51 | 54 | 49 | 17 | 171 | |||
| 4.5-7.5 cm | 330 | 188 | 230 | 241 | 989 | 71 | 49 | 43 | 33 | 196 | |||
| ≥ 7.5 cm | 137 | 62 | 73 | 140 | 412 | 35 | 12 | 17 | 41 | 105 | |||
| Retrieved lymph nodes | 0.901 | 0.900 | 0.121 | ||||||||||
| ≥ 15 | 499 | 323 | 348 | 342 | 1512 | 119 | 87 | 84 | 66 | 356 | |||
| < 15 | 202 | 118 | 136 | 135 | 591 | 38 | 28 | 25 | 25 | 116 | |||
| T Stage | < 0.001 | < 0.001 | 0.097 | ||||||||||
| T1 | 42 | 52 | 27 | 6 | 127 | 13 | 17 | 3 | 6 | 39 | |||
| T2 | 81 | 74 | 60 | 28 | 243 | 22 | 29 | 13 | 2 | 66 | |||
| T3 | 57 | 54 | 41 | 19 | 171 | 10 | 7 | 7 | 6 | 30 | |||
| T4a | 435 | 229 | 309 | 331 | 1304 | 91 | 57 | 79 | 63 | 290 | |||
| T4b | 86 | 32 | 47 | 93 | 258 | 21 | 5 | 7 | 14 | 47 | |||
| N Stage | < 0.001 | < 0.001 | 0.194 | ||||||||||
| N0 | 701 | 0 | 0 | 0 | 701 | 157 | 0 | 0 | 0 | 157 | |||
| N1 | 0 | 316 | 68 | 21 | 405 | 0 | 75 | 16 | 15 | 106 | |||
| N2 | 0 | 119 | 216 | 84 | 419 | 0 | 26 | 46 | 3 | 75 | |||
| N3a | 0 | 6 | 184 | 215 | 405 | 0 | 11 | 43 | 35 | 89 | |||
| N3b | 0 | 0 | 16 | 157 | 173 | 0 | 3 | 4 | 38 | 45 | |||
| TNM Stage | < 0.001 | < 0.001 | 0.066 | ||||||||||
| IA | 290 | 0 | 0 | 0 | 290 | 51 | 0 | 0 | 0 | 51 | |||
| IB | 129 | 50 | 11 | 2 | 192 | 35 | 10 | 7 | 2 | 54 | |||
| IIA | 101 | 64 | 22 | 3 | 190 | 25 | 10 | 3 | 2 | 40 | |||
| IIB | 92 | 47 | 36 | 12 | 187 | 25 | 9 | 8 | 4 | 46 | |||
| IIIA | 82 | 171 | 79 | 37 | 369 | 20 | 66 | 6 | 11 | 103 | |||
| IIIB | 7 | 92 | 167 | 75 | 341 | 1 | 17 | 48 | 12 | 78 | |||
| IIIC | 0 | 17 | 169 | 348 | 534 | 0 | 3 | 37 | 60 | 100 | |||
Logistic regression analysis of the risk factors for node ratio (Nr)
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Gender | 1.004 (0.758–1.332) | 0.187 | - | - |
| Age | 1.165 (1.022–1.328) | 0.022 | 0.856 (0.640–1.146) | 0.244 |
| Tumor location | 0.382 (0.202–0.723) | 0.003 | 1.020 (0.861–1.208) | 0.973 |
| Macroscopic type | 1.430 (1.252–1.633) | < 0.001 | 0.807 (0.602–1.082) | 0.277 |
| Tumor differentiation | 1.697 (1.433–2.010) | < 0.001 | 1.045 (1.008–1.321) | 0.010 |
| Lymphovascular invasion | 1.436 (1.115–1.798) | 0.023 | 1.011 (1.002–1.230) | 0.045 |
| Perineural invasion | 1.037 (0.931–1.041) | 0.052 | - | - |
| Adjuvant chemotherapy | 0.843 (0.665–1.210) | 0.310 | - | - |
| Tumor size | 1.541 (1.326–1.791) | 0.011 | 0.903 (0.667–1.221) | 0.507 |
| Retrieved lymph node | 0.923 (0.771–1.132) | 0.123 | - | - |
| T Stage | 1.234 (1.012–1.991) | 0.023 | 1.085 (0.910–1.236) | 0.064 |
| N Stage | 3.812 (2.467–4.943) | < 0.001 | 2.631 (1.912–3.676) | < 0.001 |
OR: Odds Ratio; CI: Confidence Interval.
Spearman correlation analysis of the multicollinearity for node ratio (Nr)
| Factors | Correlation coefficient (r) | |
|---|---|---|
| Tumor differentiation | 0.166 | < 0.001 |
| Lymphovascular invasion | 0.214 | < 0.001 |
| T Stage | 0.290 | < 0.001 |
| N Stage | 0.724 | < 0.001 |
Correlation is significant at the 0.01 level (2 tailed);
r: correlation coefficient; |r| < 0.3: no correlation; 0.3 ≥ |r|: correlation exists.
Figure 2Positive linear correlation between the number of positive lymph node and Nr (R2 = 0.457) in scatter spots
Prognostic prediction by Kapplan–Meier survival analyses
| Factors | 3–year OS (%) | 5–year OS (%) | MS (months) | AIC | C–index | Log rank χ2 value | |
|---|---|---|---|---|---|---|---|
| N stage | 898.7 | 0.687 | 151.1 | < 0.001 | |||
| N0 | 85.2 | 72.5 | 124.1 (7.5–176.0) | ||||
| N1 | 76.1 | 63.4 | 113.0 (3.5–174.0) | ||||
| N2 | 67.1 | 52.8 | 99.5 (1.4–172.4) | ||||
| N3a | 42.3 | 27.5 | 29.9 (0.9–160.0) | ||||
| N3b | 26.5 | 20.4 | 23.0 (0.3–172.7) | ||||
| Nr stage | 880.1 | 0.696 | 156.7 | < 0.001 | |||
| Nr0 | 85.2 | 72.5 | 124.1 (7.5–176.0) | ||||
| Nr1 | 78.3 | 63.4 | 106.0 (1.4–160.0) | ||||
| Nr2 | 58.4 | 46.9 | 54.9 (0.3–174.0) | ||||
| Nr3 | 30.4 | 22.6 | 26.1 (0.9–172.7) | ||||
| TNM stage | 872.3 | 0.754 | 161.7 | < 0.001 | |||
| IA | 92.6 | 82.5 | 134.2 (9.3–156.2) | ||||
| IB | 87.3 | 77.2 | 121.2 (1.4–172.4) | ||||
| IIA | 81.1 | 71.6 | 101.3 (0.3–174.0) | ||||
| IIB | 79.8 | 60.6 | 92.7 (4.0–176.0) | ||||
| IIIA | 66,2 | 55.4 | 82.6 (5.4–157.2) | ||||
| IIIB | 55.9 | 46.2 | 46.6 (0.9–150.3) | ||||
| IIIC | 33.1 | 22.2 | 25.4 (0.8–172.7) | ||||
| TNrM stage | 850.4 | 0.799 | 182.3 | < 0.001 | |||
| IA | 92.6 | 82.5 | 134.2 (9.3–165.2) | ||||
| IB | 90.4 | 80.8 | 112.5 (6.5–176.0) | ||||
| IIA | 85.0 | 73.4 | 98.4 (1.4–160.9) | ||||
| IIB | 79.5 | 61.8 | 84.6 (0.3–173.1) | ||||
| IIIA | 64.3 | 57.0 | 65.4 (0.8–161.8) | ||||
| IIIB | 56.4 | 41.3 | 47.3 (0.9–175.6) | ||||
| IIIC | 30.2 | 22.4 | 24.0 (0.6–172.3) |
OS: overall survival ; MS: median survival time; AIC: Akaike Information Criterion value; C–index: concordance index.
Univariate and multivariate analyses of the patients' clinicopathologic factors by Cox regression model
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Gender | 0.825 (0.691–0.984) | 0.033 | 0.808 (0.732–1.091) | 0.301 |
| Age | 0.744 (0.637–0.869) | < 0.001 | 0.751 (0.611–0.881) | < 0.001 |
| Tumor location | 0.933 (0.852–1.022) | 0.138 | – | – |
| Macroscopic type | 1.329 (1.137–1.553) | < 0.001 | 1.016 (0.872–1.221) | 0.754 |
| Tumor differentiation | 1.109 (1.032–1.257) | 0.041 | 1.012 (0.819–1.273) | 0.288 |
| Lymphovascular invasion | 1.246 (1.129–1.478) | < 0.001 | 1.138 (0.932–1.431) | 0.064 |
| Perineural invasion | 1.051 (1.002–1.171) | 0.087 | – | – |
| Adjuvant chemotherapy | 1.244 (1.112–1.653) | 0.032 | 1.104 (0.912–1.412) | 0.136 |
| Tumor size | 1.682 (1.461–1.796) | < 0.001 | 1.181 (1.041–1.353) | 0.006 |
| Retrieved lymph node | 0.893 (0.652–1.012) | 0.211 | – | – |
| T stage | 1.539 (1.404–1.686) | < 0.001 | 1.271 (1.151–1.423) | < 0.001 |
| N stage | 1.593 (1.473–1.723) | < 0.001 | 1.209 (1.013–1.389) | 0.003 |
| Nr stage | 1.856 (1.674–2.056) | < 0.001 | 1.413 (1.147–1.698) | < 0.001 |
HR: Hazard Ratio; CI: Confidence Interval; – :not enter the regression model.
Figure 3Comparative survival analysis on discriminatory ability and accuracy
(A), survival curves of patients according to subgroups of N stage. (B), survival curves of patients according to subgroups of Nr stage. (C), survival curves of patients according to subgroups of TNM stage. (D), survival curves of patients according to subgroups of TNrM stage. The significance of difference between survival curves was calculated by the log-rank test.
Figure 4Stratified comparative survival analysis on discriminatory ability and accuracy according to the different number of retrieved lymph nodes
(A, B): survival curves of patients with retrieved lymph node ≥ 15 in terms of subgroups of N and Nr stage. (C, D): survival curves of patients with retrieved lymph node < 15 in terms of subgroups of N and Nr stage. The significance of difference between survival curves was calculated by the log-rank test.
Figure 5Nomogram plots and calibration curves based on Nr stage
(A, B): nomogram plots and calibration curves in the training set. (C, D): nomogram plots and calibration curves in the validation set.
Comparison and validation of different cutoff points for Nr
| Authors (ref.) | Cutoff points | AIC | C-index | |
|---|---|---|---|---|
| Melis et al [ | 0,0.30,0.60 | 892.1 | 0.701 | < 0.05 |
| Deng et al [ | 0,0.13,0.80 | 900.3 | 0.698 | < 0.01 |
| Zeng et al [ | 0,0.50,0.80 | 912.4 | 0.674 | < 0.05 |
| Wang et al [ | 0,0.067, 0.30,0.70 | 886.9 | 0.712 | < 0.05 |
| Lee et al [ | 0,0.05, 0.10,0.20, 0.30 | 998.8 | 0.675 | < 0.05 |
| Zhang et al [ | 0,0.10,0.25 | 1012.7 | 0.602 | < 0.01 |
| Wu et al [ | 0,0.20,0.50 | 862.5 | 0.772 | < 0.05 |
| Kutlu et al [ | 0,0.20,0.50 | 862.5 | 0.772 | < 0.05 |
| Zhou et al [ | 0,0.20,0.50 | 862.5 | 0.772 | < 0.05 |
| Wong et al [ | 0,0.20,0.50 | 862.5 | 0.772 | < 0.05 |
Figure 6The flow chart of patients enrolled in this study